BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival

Journal of Investigative Dermatology

Volumn 125, Issue 2, 2005, Pages 312-317

  Akslen, Lars A ^a,d   Angelini, Sabrina ^b   Straume, Oddbjørn ^a   Bachmann, Ingeborg M ^a   Molven, Anders ^a   Hemminki, Kari ^b,c   Kumar, Rajiv ^b,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Ki 67 Prognosis

Indexed keywords

B RAF KINASE; KI 67 ANTIGEN; BRAF PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CODON; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MICROVASCULATURE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE N RAS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TUMOR CELL; TUMOR VOLUME; CELL DIVISION; FOLLOW UP; GENETICS; MORTALITY; ONCOGENE RAS; PATHOLOGY; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN TUMOR;

CELL DIVISION; FOLLOW-UP STUDIES; GENES, RAS; HUMANS; MELANOMA; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 24344490303     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23788.x     Document Type: Article

References (26)

1. Arbiser JL: Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase). J Invest Dermatol 121:xiv, 2003
2. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902-908, 1970
3. Brose MS, Volpe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000, 2002
4. Clark WJ, From L, Bernardino E, Mihm M: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29: 705-727, 1969
5. Cohen Y, Rosenbaum E, Begum S, et al: Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 10: 3444-3447, 2004
6. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
7. Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ: Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 117:1483-1489, 2001
8. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63:3883-3885, 2003
9. Edwards RH, Ward MR, Wu H, et al: Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 41:270-272, 2004
10. Govindarajan B, Bai X, Cohen C, et al: Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 278:9790-9795, 2003
11. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R, Rapp UR: Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3:6, 2004
12. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, Hemminki K: BRAF mutations in metastatic melanoma: A possible association with clinical outcome. Clin Cancer Res 9:3362-3368, 2003a
13. Kumar R, Angelini S, Hemminki K: Activating BRAF and N-Ras mutations in sporadic primary melanomas: An inverse association with allelic loss on chromosome 9. Oncogene 22:9217-9224, 2003b
14. Kumar R, Angelini S, Snellman E, Hemminki K: BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 122:342-348, 2004
15. Maldonado JL, Fridlyand J, Patel H, et al: Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878-1890, 2003
16. Norusis M: SPSS Advanced Statistics 6.1. SPSS Inc., 1994
17. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J: Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: Mutations occur early and persist throughout tumor progression. Clin Cancer Res 8:3468-3474, 2002
18. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J: NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9:6483-6488, 2003
19. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19-20, 2003
20. Shinozaki M, Fujimoto A, Morton DL, Hoon DS: Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10:1753-1757, 2004
21. Straume O, Akslen LA: Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 78:1211-1219, 1996
22. Straume O, Akslen LA: Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 159: 223-235, 2001
23. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA: Significant impact of promoter hypermethylation and the 540 C > T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 161:229-237, 2002
24. Straume O, Sviland L, Akslen LA: Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 6:1845-1853, 2000
25. Yazdi AS, Palmedo G, Flaig MJ, Kutzner H, Sander CA: SP-11 different frequencies of a BRAF point mutation in melanocytic skin lesions. Pigment Cell Res 16:580, 2003
26. Yuen ST, Davies H, Chan TL, et al: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62:6451-6455, 2002